BOL 148/neuroprotectant agent combination therapy - Havn Life Sciences
Alternative Names: BOL-148/neuroprotectant agent combination therapy - Havn Life Sciences; Neuroprotectant agent/BOL 148 combination therapy - Havn Life SciencesLatest Information Update: 16 Jun 2021
At a glance
- Originator Bolt Biotherapeutics
- Class Analgesics; Antidementias; Antidepressants; Anxiolytics; Ergolines; Ergot alkaloids; Neuroprotectants; Neuropsychotherapeutics; Small molecules
- Mechanism of Action Serotonin 5-HT2A receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cluster headache